News Article

BD to Acquire Cellular Research to Develop a Leading Genomics Platform for Single Cell Analysis
Date: Aug 25, 2015
Source: PR Newswire ( click here to go to the source)

Featured firm in this article: Cellular Research Inc of Menlo Park, CA

FRANKLIN LAKES, N.J., Aug. 25, 2015 -- BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), today announced it has completed the acquisition of Cellular Research, Inc.

BD is a global leader in characterizing and isolating single cells for analysis, with more than 30 years of experience in developing cell sorting technologies, known collectively as flow cytometry. This acquisition sets the stage for the next generation of commercial tools in the field of single cell genomic analysis, widely acknowledged by leading academic and industry researchers as the next frontier of biological discovery and clinical advancement. Cellular Research has developed advanced tools for massively parallel single cell genetic analysis based on their proprietary Molecular Indexing technology to enable gene expression profiles from single cells.

Combined, the BD and Cellular Research technologies provide researchers an integrated sample prep workflow to quantify and study gene expression in large numbers of individual cells, enabling higher resolution biology. The comprehensive workflow is intended to enable researchers to make new discoveries in single cell analysis, promoting the understanding of the genomic diversity of single cells and helping to identify new approaches for targeted clinical diagnostics and therapies in important fields such as immunology, immune-oncology and personalized medicine.

"The acquisition of Cellular Research, combined with our existing cell sorting technology, will provide our customers with a more complete and simplified workflow solution for single cell analysis," said Linda Tharby, executive vice president and president of BD Life Sciences. "The addition of Cellular Research builds on our GenCell acquisition and underscores BD's commitment to a genomics strategy focused on next generation sequencing (NGS) sample preparation."

Since September 2014, BD and Cellular Research have had a collaboration to develop single cell analysis workflows for Cellular Research's Precise product line and BD's FACS™ instruments and software. The collaboration resulted in a study presented at Advances in Genome Biology and Technology (AGBT) Meeting that demonstrated the combined workflow enhances the detection and quantification of gene expression in single and/or multiple cell samples.

"Integrating BD's single cell sorting capabilities and world-leading expertise with our next generation single cell genomic technologies will provide researchers with a scalable, cost-effective approach to high resolution gene expression studies," said Stephen Fodor, Ph.D., chief executive officer and co-founder of Cellular Research. "We are excited about the possibilities we can offer researchers by combining our expertise, and believe it has the potential to meet several unmet needs in single cell genomics research."

Additional terms of the agreement were not disclosed.

About BD

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

For more information on BD, please visit

About Cellular Research

Cellular Research, Inc. is a biotechnology research and development company founded by innovators from Silicon Valley and Stanford University. Our mission is to develop and commercialize a new generation of highly sensitive life science technologies and products. In addition to introducing a portfolio of research products, the Company has an active partnership program with pharmaceutical and diagnostics companies advancing clinical applications. For more information, please visit


BD, BD Logo and BD FACS are trademarks of Becton, Dickinson and Company. Cellular Research, Cellular Research Logo, Precise and Molecular Indexing are trademarks of Cellular Research, Inc.